Apr 27
Noxopharm has announced positive results from InhaTarget Therapeutics, a company with a unique inhalation-based delivery system that is testing Sofra™ technology platform assets.
Read the announcement here: noxopharm.com/pdf/deb770c3-2…
3
43
18 Apr 2024
At #ELCC24 we presented a poster on the phI/II study testing inhaled #cisplatin systemic chemo-IO for pts with tx-naive stage IV #NSCLC 🫁
A trial conducted by @inhatarget, a spin-off from @ULBruxelles w/ several academic hospitals in #Belgium
@JulesBordet @OncoAlert @myESMO
Prof @MarianaBrandao0, medical oncologist at Institute Jules Bordet, Hôpital Universitaire de Bruxelles presents a phase I/IIa study that aims to investigate the efficacy and safety of dry powder inhaled cisplatin in stage IV NSCLC patients.
1
3
10
2,562
11 Dec 2022
Inhaled dry powder cisplatin increases antitumour response to anti-PD1 in a murine lung cancer model.
| Rémi Rosière @inhatarget |
[50 days' free access]
#drypowder #inhalation #cisplatin #lungcancer
authors.elsevier.com/sd/arti…
1
6
16
6 Dec 2022
Inhaled dry powder cisplatin increases antitumour response to anti-PD1 in a murine lung cancer model.
| Rémi Rosière @inhatarget | @CRSBeNeLuxFr
#drypowder #inhalation #cisplatin
doi.org/10.1016/j.jconrel.20…
1
1
8
La spin-off de l'@ULBruxelles @inhatarget a développé une technologie novatrice pour administrer une #chimiothérapie par inhalation afin de traiter le #cancer du poumon. ⬇️lecho.be/lecho/general/inhat… Via @GossetOlivier1
2
2
21 Dec 2018
Inhaled chemotherapy: a promising solution to treat lung cancer scitecheuropa.eu/inhaled-che… via @ScitechEuropa #inhatarget #lungcancer #inhalation
1
1
La #startup #Inhatarget développe une #chimiothérapie par inhalation contre le #cancer du poumon : buff.ly/1ZgGLzj via @ULBruxelles
2
3